Eterna

Quick links to important sections

Eterna

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eterna

Quick Facts

Property Description
Active ingredient Ondansetron
Forms Tablet, Orally Disintegrating Tablet (ODT), Oral solution, Solution for injection
Pharmacological class Selective Serotonin 5-HT3 Receptor Antagonist
Common purpose Prevention and relief of nausea and vomiting
Origin Synthetic

What Type of Medicine is Eterna and What is its Purpose?

Eterna is a synthetic, single-ingredient medicinal product used to prevent and relieve the symptoms of nausea and vomiting (emesis), classifying it broadly as an antiemetic. The active ingredient is Ondansetron, a substance with a widely recognized role in clinical practice for treating these symptoms. Ondansetron's effectiveness, particularly in challenging scenarios, is clinically recognized, establishing its role in this therapeutic area.


Composition and Pharmacological Identity of Ondansetron

The composition of Eterna relies on the molecule Ondansetron, typically formulated as the hydrochloride salt, making it a highly targeted synthetic product. Pharmacologically, Ondansetron is precisely defined as a selective serotonin 5-HT3 receptor antagonist. This specific identity means the drug acts by selectively blocking the effects of the chemical messenger serotonin (5-HT) at the 5-HT3 receptors found in both the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the brain. By blocking these specific signals, the medication helps to effectively suppress the urge to vomit.


Available Forms and Routes of Administration

Eterna is supplied in several dosage forms to accommodate various patient needs, allowing for both oral and parenteral routes of administration. The oral forms include standard tablets, convenient Orally Disintegrating Tablets (ODTs), and a liquid oral solution. For situations requiring immediate action or when oral intake is compromised, the drug is also formulated as a sterile solution for injection, which facilitates intravenous administration using an aqueous base. This range of preparations ensures that Ondansetron can be delivered effectively regardless of the severity or clinical context of the patient's symptoms.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Eterna?

Possible Side Effects and Safety Information

The safety profile of Eterna (Ondansetron) is defined by regulatory documents that classify potential adverse reactions based on frequency and affected system-organ class.

Frequency Classification Examples of Reactions
Very Common Headache
Common Constipation, sensation of warmth or flushing
Uncommon Seizures, movement disorders, arrhythmias, increases in liver function tests
Rare Immediate hypersensitivity reactions, QTc prolongation, transient visual disturbances

Serious adverse reactions documented in official labeling include QTc interval prolongation, which carries the risk of a potentially fatal heart rhythm disturbance known as Torsade de Pointes. Cases of severe hypersensitivity reactions, including anaphylaxis, and reports of Serotonin Syndrome (especially with concurrent use of other serotonergic medicines) are also noted. Caution is required in patients with pre-existing conditions that predispose to QTc prolongation, such as electrolyte abnormalities or congestive heart failure.

Specific safety considerations exist for certain populations. For patients with moderate or severe hepatic impairment, a constraint on the maximum daily dose is advised. The official label also notes that the use of Ondansetron may potentially mask symptoms of progressive intestinal obstruction due to its effect on gastrointestinal motility.

Overdose and Emergency Response

A suspected overdose of Eterna (Ondansetron) requires immediate medical attention. Officially documented clinical manifestations of an overdose may include hypotension (low blood pressure), severe constipation, and specific cardiac irregularities like transient second degree AV block. Transient visual disturbances, such as blurred vision or temporary blindness, have also been observed.

The official regulatory profile emphasizes the risk of serious or life-threatening cardiovascular outcomes, notably QTc prolongation and the potential for the severe rhythm disturbance Torsade de Pointes. Additionally, there is a documented risk of Serotonin syndrome, which is especially pertinent if Eterna is co-administered with other serotonergic medicines.

Immediate medical help must be sought if any overdose is suspected. As no specific antidote is known, the required management involves administering symptomatic and supportive therapy appropriate to the manifestations. Due to the documented cardiac risk, official guidance recommends ECG monitoring. Regulatory labeling also notes that Eterna must be avoided in patients with congenital long QT syndrome due to the heightened risk of QTc prolongation.

Therapeutic Uses of Eterna

What Eterna Treats: Main Uses and Benefits

The role of Eterna is to provide support against the symptoms related to physical discomfort of severe nausea and vomiting. The medicine is applied across domains where additional symptomatic support is needed to prevent and manage these specific, distressing manifestations.

The primary uses of Eterna involve managing symptoms associated with chemotherapy-induced sickness, radiation-induced sickness, and sickness following surgery.


Supporting Oncology Patients: Chemotherapy and Radiation-Induced Sickness

Eterna is commonly used across conditions characterized by periods of heightened symptoms associated with cancer treatments. It is applied in clinical settings that involve acute or unstable symptom patterns, helping to prevent the intense nausea and vomiting. This support helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability.

Preventing Postoperative and Procedural Discomfort

The medication plays a role in managing symptoms that interfere with daily functioning during the recovery phase following medical interventions. It is commonly used when short-term symptomatic assistance is needed to prevent sickness, particularly after general anesthesia and surgery. By managing these symptom clusters that may become intense or disruptive, Eterna provides support that helps ease the overall symptom burden.


Quick Fact: Symptomatic Relief

Symptom Targeted Primary Therapeutic Benefit
Nausea (urge to vomit) Provides symptomatic relief, easing discomfort
Vomiting (emesis) Helps manage the intensity and frequency of acute episodes

Eligibility and Restrictions for Use

Who Can and Cannot Use Eterna?

Eligibility for Eterna (Ondansetron) is defined by specific rules established in government regulatory documentation, addressing age, existing medical conditions, and concurrent medication use.

Contraindications and Restrictions

Category Regulatory Wording
Absolute Contraindication Patients with known hypersensitivity to ondansetron or those taking apomorphine must not use this medicine.
Strong Restriction Use is not recommended or should be avoided in patients with a history of congenital long QT syndrome.
Hepatic Impairment Patients with severe hepatic impairment must adhere to a strict maximum daily dose limitation of 8 mg.
Conditional Use Caution is mandated for patients with uncorrected electrolyte imbalances (e.g., low potassium) or Congestive Heart Failure (CHF).

Age and Physiological Eligibility

Eterna is approved for Postoperative Nausea and Vomiting (PONV) in pediatric patients from 1 month of age and for Chemotherapy-Induced Nausea and Vomiting (CINV) from 6 months of age. Safety and efficacy are not established in infants under 1 month. For renal impairment (kidney problems), regulatory documents state no dosage adjustment is required.

Use in pregnancy is restricted to cases where other treatments have failed to manage severe sickness. Use during lactation requires a benefit versus risk assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The established interaction profile for Eterna (Ondansetron) is defined by mandatory restrictions and documented pharmacokinetic (PK) and pharmacodynamic (PD) effects, based on official government regulatory labeling.

Classification Interacting Entity / Category Officially Documented Effect
Contraindicated Apomorphine Profound hypotension and loss of consciousness
PK (Clearance) Potent CYP3A4 Inducers (e.g., Phenytoin, Rifampin) Increased clearance and decreased blood concentrations
PD (Additive Risk) Serotonergic Drugs (e.g., SSRIs, SNRIs) Risk of developing Serotonin Syndrome
PD (Cardiac Risk) QT-Prolonging Drugs Additive risk of QT interval prolongation

The single absolute contraindication noted in regulatory documents is co-administration with Apomorphine. The pharmacokinetic structure involves Eterna's metabolism primarily by the CYP3A4 enzyme system. Substances that accelerate the activity of this enzyme, such as Carbamazepine, cause a significant, documented reduction in Eterna's systemic exposure. Furthermore, patients with severe hepatic impairment exhibit significantly reduced plasma clearance and prolonged half-life, which must be considered. The presence of electrolyte abnormalities, such as hypokalaemia or hypomagnesaemia, are noted as conditions that increase the cardiac risk associated with Eterna. The medicine's official label states that it may be administered with or without food.

Mechanism of Action

Eterna's action is defined by a highly selective molecular mechanism targeting the serotonergic system. The active ingredient, Ondansetron, works as a competitive antagonist at the 5- HT3 receptor, preventing the excitatory neurotransmitter serotonin (5- HT) from binding and initiating a signaling cascade. This blockade targets 5- HT3 receptors, which are key components of the physiological pathways that govern the emetic reflex.


Dual Mechanism: Central and Peripheral Pathway Blockade

The drug's mechanism involves simultaneous action at two critical anatomical sites to interrupt the emetic signal. Peripherally, it blocks 5- HT3 receptors on vagal afferent neurons in the gastrointestinal tract, inhibiting signal transmission that often originates from the gut. Centrally, it blocks these same receptors within the Chemoreceptor Trigger Zone (CTZ) in the brainstem, preventing chemical triggers carried in the blood from activating the final emesis pathway. This dual inhibition of afferent signaling raises the threshold required to activate the central Vomiting Center, which is the physiological consequence of modulating this reflex arc.


Mechanistic Limitations to Non-Serotonergic Inputs

The mechanism is highly specific to the 5- HT3 receptor, meaning its physiological effects are restricted to those pathways where serotonin plays the dominant signaling role. Consequently, this selective antagonism does not affect pathways driven by other neurotransmitter systems, such as the histaminergic ( H1) or muscarinic ( M1) systems. This explains the mechanistic constraint: the drug does not affect signaling processes mediated by vestibular inputs, as those processes are regulated by different receptor families.

Dosage and Administration Information

Eterna (Ondansetron) is approved for use via both oral and parenteral routes of administration, accommodating varying needs for onset of action and clinical context. The oral forms include standard tablets, orally disintegrating tablets (ODTs), and a solution, while the parenteral form is available as a solution for intravenous (IV) or intramuscular (IM) injection. This variety in delivery ensures suitability regardless of a patient's ability to tolerate oral intake.


The official dosing regimen is strictly tied to the type of medical procedure. For instance, prevention associated with highly emetogenic chemotherapy requires a single oral dose of 24 mg administered prior to the procedure. For situations such as moderately emetogenic chemotherapy, an initial dose is followed by a short maintenance schedule of 8 mg taken twice daily for one to two days. For postoperative use, a single 4 mg dose is administered via the IV or IM route.


Parenteral use is subject to specific procedural constraints; the solution must be diluted in compatible intravenous fluids and infused over a controlled duration, typically 2 to 15 minutes, depending on the dose. The maximum total daily dose must be lowered to 8 mg for patients with severe hepatic impairment, irrespective of the administration route.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eterna

Evidence for Preventing Chemotherapy-Induced Sickness

Research has explored the use of Eterna (Ondansetron) for managing the symptoms associated with chemotherapy-induced nausea and vomiting (CINV). Studies conducted include a high volume of short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Studies were conducted in both adults and pediatric patients (children over 6 months) who were undergoing chemotherapy. Trials tracked the incidence of vomiting episodes and whether patients required rescue antiemetic medicine. Outcomes related to the rate of complete response (absence of vomiting) were reported across the acute phase (the first 24 hours) and sometimes extending to five days (delayed phase). Follow-up durations were typically limited, meaning that information about long-term outcomes remains not fully established. Data for certain groups remain insufficient, particularly for adults over 75 years of age.

Evidence for Preventing Sickness Following Surgery

Research has also explored the use of Eterna in studies evaluating sickness following general anesthesia. The evidence relies on a large collection of double-blind, placebo-controlled RCTs and systematic reviews that evaluated outcomes related to sickness after surgery. Studies included diverse adults and pediatric patients (children over 1 month). Studies explored short-term changes, measuring outcomes related to acute episodes, such as the incidence of nausea and vomiting/retching. The data show patterns related to the short-term incidence of sickness within the 24 hours following surgery. Regulatory documents note limited information for both the prevention and treatment of sickness after surgery in elderly patients (over 65 years) and for children under 2 years of age.

Research Context for Radiation-Induced Sickness

Research has also explored the use of Eterna in studies evaluating sickness associated with Radiation-Induced Nausea and Vomiting (RINV). The studies examined outcomes focusing on the degree of complete protection from emesis (vomiting) and treatment failure rates. The volume of dedicated research for RINV is smaller and the evidence is more heterogeneous compared to CINV and PONV studies.

Key Studies & References

  1. Ondansetron - StatPearls - NCBI Bookshelf (Summary of Indications and Uses)
  2. Ondansetron 2 mg/ml Solution for Injection and Infusion - Summary of Product Characteristics (EMA/HPRA)
  3. Public Assessment Report - Ondansetron Aurobindo (EMA/MEB) - Indications and Pediatric Age Limits
  4. Management of vomiting in children and young people with gastroenteritis: ondansetron (NICE Evidence Summary)
  5. Systematic review of ondansetron for the prevention and treatment of postoperative nausea and vomiting in adults (Cochrane/NCBI Abstract)

Frequently Asked Questions (FAQ)

Common questions about Eterna (FAQ)

Q: Can Eterna be used by people over 65?

According to official product information, dose adjustments are not recommended for the elderly. Clinical studies indicated that the safety and effectiveness profile was similar for patients over the age of 65 compared to younger adults for the approved indications.


Q: Is Eterna safe for pregnant or breastfeeding women, according to official sources?

Regulatory documents note there are no adequate and well-controlled human studies in pregnant women. Animal studies did not show evidence of harm; however, data from animal studies may not always reflect human outcomes. For breastfeeding, it is unknown if the medicine is excreted into human milk, and some official guidance advises against use.


Q: Does Eterna interact with alcohol?

Official drug interaction lists do not typically cite alcohol as a direct drug-drug interaction with Eterna. However, alcohol consumption may itself cause nausea and vomiting, which could interfere with the management of the underlying condition the medicine is being used for.


Q: Can Eterna be crushed or split?

Official guidance for the standard tablet form instructs patients to swallow the medicine whole and not to crush, chew, or split it. The alternative forms, such as ODTs or liquid solution, are available as supplied.


Q: Does Eterna affect blood pressure?

Eterna is not a blood pressure medication, but the official label notes a serious risk of a profound drop in blood pressure (hypotension) if it is used together with the medicine Apomorphine. The concomitant use of these two medicines is formally contraindicated.


Q: How quickly does Eterna leave the body?

The elimination half-life of Eterna—the time it takes for the concentration of the drug in the body to be reduced by half—is approximately 3 to 4 hours in healthy adults. Based on the elimination half-life, the substance is estimated to be largely cleared from the body within approximately 16 to 20 hours.


Q: What is the maximum duration Eterna has been studied for in clinical trials?

Clinical studies and approved dosing regimens focus on short-term use. For instance, the approved use following chemotherapy is typically for a period of 1 to 2 days, and clinical trials typically extended monitoring to up to five days for the prevention or relief of symptoms.


Q: Is Eterna used to prevent something or to treat an active condition?

The medicine is officially indicated for both purposes. It is approved for the prevention of sickness associated with chemotherapy, radiation, and surgery, as well as for the relief (treatment) of established postoperative sickness.


Q: Does Eterna have a black box warning, and what does it mean?

The medicine label does not carry a Black Box Warning. Warnings are provided about the potential risks of serious effects, such as QTc interval prolongation (an effect on heart rhythm).


Q: What kind of specialist usually prescribes Eterna?

Eterna is most often prescribed in specific medical contexts, such as oncology (for patients receiving chemotherapy or radiation treatment) and perioperative medicine (to manage sickness related to surgery). It is prescribed by the healthcare professional managing that specific part of a person's care.


Q: Does Eterna interact with grapefruit or grapefruit juice?

Official information states the medicine can be taken with or without food. Eterna is metabolized by an enzyme system (CYP3A4) that can be affected by certain food substances like grapefruit. However, a formal interaction is not explicitly listed in all regulatory documents.


Q: What is the half-life of Eterna?

The elimination half-life, which describes how quickly the medicine is cleared, is approximately 3 to 4 hours in healthy adults. This time can be longer in specific groups, such as the elderly or those with severe liver problems.


Q: Are there different versions of Eterna available (e.g., tablet, liquid)?

Yes, official documents indicate the medicine is available in several dosage forms. These include a standard oral tablet, an orally disintegrating tablet (ODT), a liquid oral solution, and a solution for injection (IV or IM).


Q: Is Eterna the same kind of medicine as [similar drug name]?

Eterna belongs to a specific pharmacological category known as selective serotonin 5- HT3 receptor antagonists. Other medicines may also belong to this same class, meaning they work similarly, but they are chemically distinct drugs.


Q: Why is Eterna only available by prescription?

The medicine is a potent, controlled drug with official warnings concerning potential serious side effects, particularly effects on heart rhythm. Due to these potential risks, it must be used only under the supervision of a licensed healthcare provider.


Q: How long does it typically take for Eterna to start working?

The medicine is designed to act rapidly. For many uses, such as preventing sickness from chemotherapy or surgery, it is administered shortly beforehand (e.g., 30 minutes before treatment) to ensure the medication is present in the system when symptoms are anticipated to begin.


Q: Is Eterna considered a long-term treatment?

No, clinical studies and the approved indications are focused on short-term use. The approved dosing schedules are typically for a limited period, often 1 to 5 days, to manage sickness related to a specific medical event.


Q: What should I do if I miss a dose of Eterna?

Official patient information typically provides guidance for scheduled medicines, such as taking the missed dose as soon as it is remembered. Always follow the specific instructions provided by your prescriber or pharmacist.


Q: Does Eterna cause weight changes?

Weight change is not listed among the common or frequent side effects documented in the medicine's official safety profile. The reported side effects generally involve the central nervous system or gastrointestinal tract.


Q: Are there any specific organs that Eterna affects the most?

The official safety profile notes potential effects on multiple body systems. Specific warnings involve the Cardiovascular system (heart rhythm) and the Hepatic system (liver function), in addition to common effects on the Gastrointestinal system (constipation).


Q: Is Eterna addictive or habit-forming?

Eterna is not listed as a controlled substance by the US DEA and is not described in official regulatory labeling as having any potential for abuse or as being habit-forming.


Q: Does Eterna affect sleep?

The official safety profile lists central nervous system effects, such as headache and dizziness, as common side effects. These effects may indirectly influence a person's rest or sleep patterns.


Q: What happens in the body when Eterna 'wears off'?

The medicine works by blocking specific serotonin 5- HT3 receptors in the body. As the drug is naturally metabolized and cleared from the system (based on its half-life), this blockade wears off, and the body’s natural serotonin signaling pathways are restored.


Q: Do I need to change my diet while using Eterna?

The official label states that the medicine can be administered with or without food. There are no general dietary changes or restrictions described as mandatory for its use.


Q: Does Eterna lose effectiveness over time?

The approved indications for Eterna are for short-term use. There are no documented reports in official regulatory documents that the medicine loses effectiveness over time (tachyphylaxis) when used for its approved short-term indications.


Q: Can I take Eterna with common cold or flu medications?

Official documents provide warnings about established drug classes that may interact with Eterna, notably Serotonergic Drugs. The interaction profile for any specific cold or flu medicine must be reviewed by a healthcare provider.


Q: Is Eterna safe for teenagers (under 18)?

Official approval for the use in pediatric patients begins from 1 month of age (for postoperative sickness) and 6 months of age (for chemotherapy-induced sickness) for specific indications.


Q: How soon after stopping Eterna will the effects be gone?

Based on the medicine's elimination half-life of 3 to 4 hours, the active substance is expected to be largely cleared from the body within 16 to 20 hours after the last dose, and it is estimated that the drug's effects will have ceased by this time.


Q: Will Eterna affect my ability to get pregnant or have children?

Nonclinical toxicity studies performed on animals revealed no evidence of impaired fertility or general reproductive performance in male or female rats. Comparable fertility data from human studies are not specifically described in official documents.


Q: What are the most common reasons patients stop using Eterna?

Official documents describe that the medicine must be discontinued if the patient experiences severe reactions. These include a serious allergic reaction (hypersensitivity), a dangerous buildup of serotonin (Serotonin Syndrome), or symptoms of myocardial ischemia.


Q: How does Eterna interact with birth control pills?

Official regulatory documents and established interaction profiles do not typically list an established drug-drug interaction between Eterna and most common oral contraceptive pills (birth control pills).


Q: Are there any warnings about driving or operating machinery while taking Eterna?

Yes, official patient guidance notes that the medicine may cause dizziness or other effects on the central nervous system. Users should be aware of how they react to the medicine before driving or operating machinery.


Q: Is it normal to feel [mild, non-serious symptom] when starting Eterna?

The medicine’s official safety profile lists several effects as very common or common, which may be expected upon starting treatment. These include headache, a sensation of warmth or flushing, and constipation.

How should Eterna be stored and disposed of?

The official storage and disposal guidelines for Eterna are defined by specific regulatory requirements to maintain product stability and ensure safety.

Storage Conditions

Oral forms (tablets, solution) should be kept in their original container and stored at controlled room temperature, protected from both moisture and light.

Eterna injection solution must also be protected from light and stored within a mandated temperature range (typically 20 C to 25 C). After dilution, the stability period is limited, and opened ampoules must be used immediately.

Child Safety

All forms of Eterna must be kept out of the sight and reach of children in a secure, inaccessible location.

Disposal

Expired or unused Eterna should not be disposed of via wastewater or household trash. The required disposal method is typically a drug take-back program or returning the product to a pharmacist to comply with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eterna found in:

A-Z Index: